Inflammatory Bowel Disease Provoked by Etanercept: Report of 443 Possible Cases Combined from an IBD Referral Center and the FDA

Digestive Diseases and Sciences

Volumn 61, Issue 6, 2016, Pages 1772-1774

  O’Toole, Aoibhlinn ^a   Lucci, Matthew ^a   Korzenik, Joshua ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Anti TNF; Crohn s disease; Etanercept; FDA; Inflammatory bowel disease; Paradoxical; Ulcerative colitis

Indexed keywords

ETANERCEPT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR;

ADULT; AGED; ANKYLOSING SPONDYLITIS; CHILD; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; ICD-9; JUVENILE RHEUMATOID ARTHRITIS; LETTER; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PHENOTYPE; POLYARTHRITIS; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; TREATMENT DURATION; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; INFLAMMATORY BOWEL DISEASE; MIDDLE AGED; POSTMARKETING SURVEILLANCE; UNITED STATES;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ETANERCEPT; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84952944144     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-4007-z     Document Type: Letter

References (17)

1. Vermeire S, Noman M, Van Assche G, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn’s disease: a prospective cohort study. Gastroenterology. 2003;125:32–39.
2. Subramanian S, Yajnik V, Sands BE, et al. Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent. Inflamm Bowel Dis. 2011;17:99–104.
3. Fouache D, Goeb V, Massy-Guillemant N, et al. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study. Rheumatology (Oxford). 2009;48:761–764.
4. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001;121:1088–1094.
5. Toussirot E, Houvenagel E, Goeb V, et al. Development of inflammatory bowel disease during anti-TNF-alpha therapy for inflammatory rheumatic disease: a nationwide series. Joint Bone Spine. 2012;79:457–463.
6. Murphy SN, Chueh HC. A security architecture for query tools used to access large biomedical databases. In: Proceedings AMIA Symposium 2002:552–556.
7. FDA. The Adverse Event Reporting System (AERS) U.S. Food and Drug Administration. Volume 2014.
8. Quartier P, Taupin P, Bourdeaut F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 2003;48:1093–1101.
9. Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease. Gastroenterology. 2003;124:1774–1785.
10. Marotte H, Cimaz R. Etanercept—TNF receptor and IgG1 Fc fusion protein: is it different from other TNF blockers? Expert Opin Biol Ther. 2014;14:569–572.
11. Tichy M, Hercogova J. Manifestation of Crohn’s disease in a young woman during the course of treatment for severe form of chronic plaque psoriasis with etanercept. Dermatol Ther. 2014;27:211–214. doi:10.1111/dth.12119.
12. Wiegering V, Morbach H, Dick A, et al. Crohn’s disease during etanercept therapy in juvenile idiopathic arthritis: a case report and review of the literature. Rheumatol Int. 2010;30:801–804.
13. Jethwa H, Mann S. Crohn’s disease unmasked following etanercept treatment for ankylosing spondylitis. BMJ Case Rep. 2013. doi:10.1136/bcr-2013-009166.
14. Krishnan A, Stobaugh DJ, Deepak P. Assessing the likelihood of new-onset inflammatory bowel disease following tumor necrosis factor-alpha inhibitor therapy for rheumatoid arthritis and juvenile rheumatoid arthritis. Rheumatol Int. 2015;35:661–668. doi:10.1007/s00296-014-3133-9.
15. Cohen R, Robinson D Jr, Paramore C, et al. Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001–2002. Inflamm Bowel Dis. 2008;14:738–743.
16. Rudwaleit M, Baeten D. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol. 2006;20:451–471.
17. Haraoui B, Krelenbaum M. Emergence of Crohn’s disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action. Semin Arthritis Rheum. 2009;39:176–181.